American College Of Cardiology 2006 Meeting In Brief
This article was originally published in The Gray Sheet
Executive Summary
Drug-eluting stent study looks at long lesions: Johnson & Johnson/Cordis claimed victory for its Cypher stent over Boston Scientific's Taxus in the treatment of long, complex lesions, based on results of its LONG DES-II trial presented at the American College of Cardiology meeting in Atlanta on March 12. Six months after randomizing 500 patients with lesions greater than 25 mm to either Cypher or Taxus, investigators at the University of Ulsan, Seoul, Korea recorded less in-stent late loss among the Cypher group (0.05 mm +0.22 mm lumen diameter loss index for Cypher, versus 0.25 mm +0.35 mm for Taxus). Investigators also recorded 71% less in-segment restenosis for the Cypher group compared to Taxus...